BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 23949739)

  • 1. Antiemetics: American Society of Clinical Oncology clinical practice guideline update.
    Basch E; Prestrud AA; Hesketh PJ; Kris MG; Feyer PC; Somerfield MR; Chesney M; Clark-Snow RA; Flaherty AM; Freundlich B; Morrow G; Rao KV; Schwartz RN; Lyman GH;
    J Clin Oncol; 2011 Nov; 29(31):4189-98. PubMed ID: 21947834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 2023 Updated MASCC/ESMO Consensus Recommendations: prevention of radiotherapy- and chemoradiotherapy-induced nausea and vomiting.
    Ruhlmann CH; Jordan K; Jahn F; Maranzano E; Molassiotis A; Dennis K
    Support Care Cancer; 2023 Dec; 32(1):26. PubMed ID: 38097904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acupuncture compared with placebo acupuncture in radiotherapy-induced nausea--a randomized controlled study.
    Enblom A; Johnsson A; Hammar M; Onelöv E; Steineck G; Börjeson S
    Ann Oncol; 2012 May; 23(5):1353-1361. PubMed ID: 21948812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pharmacological basis of
    Muhammad N; Ullah S; Abu-Izneid T; Rauf A; Shehzad O; Atif M; Khan H; Naz H; Herrera-Calderon O; Khalil AA; Uddin MS
    Toxicol Rep; 2020; 7():1305-1310. PubMed ID: 33024704
    [No Abstract]   [Full Text] [Related]  

  • 5. Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials.
    Rapoport BL; Chasen MR; Gridelli C; Urban L; Modiano MR; Schnadig ID; Poma A; Arora S; Kansra V; Schwartzberg LS; Navari RM
    Lancet Oncol; 2015 Sep; 16(9):1079-1089. PubMed ID: 26272769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of fosaprepitant combined with tropisetron plus dexamethasone in preventing nausea and emesis during fractionated radiotherapy with weekly cisplatin chemotherapy: interim analysis of a randomized, prospective, clinical trial using competing risk analysis.
    Xie S; Huang R; Zhan Y; Cai Q; Wu Y; Huang K; Lin X; Wang R; Yan Y; Xie R; Wang S; Zeng C; Chen C
    Support Care Cancer; 2023 Oct; 31(12):640. PubMed ID: 37851143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fosaprepitant Weekly vs Every 3 Weeks for the Prevention of Concurrent Chemoradiotherapy-Induced Nausea and Vomiting: A Pilot Randomized Clinical Trial.
    Yang Q; Zou X; Xie YL; Lin C; Ouyang YF; Liu YL; Duan CY; You R; Liu YP; Liu RZ; Huang PY; Guo L; Hua YJ; Chen MY
    JAMA Netw Open; 2023 Jul; 6(7):e2326127. PubMed ID: 37498596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A modified olanzapine-based anti-emetic regimen for the control of nausea and vomiting in patients receiving weekly cisplatin.
    Mehra N; Christopher V; Dhanushkodi M; Radhakrishnan V; Ganesan TS; Ganesharajah S; Sagar TG; Ganesan P
    Int J Clin Pharm; 2020 Apr; 42(2):662-666. PubMed ID: 32152887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolution of antiemetic studies for radiation-induced nausea and vomiting within an outpatient palliative radiotherapy clinic.
    McKenzie E; Chan D; Parsafar S; Razvi Y; McFarlane T; Rico V; Pasetka M; DeAngelis C; Chow E
    Support Care Cancer; 2019 Sep; 27(9):3245-3252. PubMed ID: 31119459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent advances in antiemetics: new formulations of 5HT
    Gilmore J; D'Amato S; Griffith N; Schwartzberg L
    Cancer Manag Res; 2018; 10():1827-1857. PubMed ID: 30013391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 2016 updated MASCC/ESMO consensus recommendations: prevention of radiotherapy-induced nausea and vomiting.
    Ruhlmann CH; Jahn F; Jordan K; Dennis K; Maranzano E; Molassiotis A; Roila F; Feyer P
    Support Care Cancer; 2017 Jan; 25(1):309-316. PubMed ID: 27624464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of palonosetron plus aprepitant in preventing chemoradiotherapy-induced nausea and emesis in patients receiving daily low-dose cisplatin-based concurrent chemoradiotherapy for uterine cervical cancer: a phase II study.
    Hanawa S; Mitsuhashi A; Matsuoka A; Nishikimi K; Tate S; Usui H; Uno T; Shozu M
    Support Care Cancer; 2016 Nov; 24(11):4633-8. PubMed ID: 27286875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prophylactic Management of Radiation-Induced Nausea and Vomiting.
    Feyer P; Jahn F; Jordan K
    Biomed Res Int; 2015; 2015():893013. PubMed ID: 26425557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Palonosetron and prednisolone for the prevention of nausea and emesis during fractionated radiotherapy and 5 cycles of concomitant weekly cisplatin-a phase II study.
    Ruhlmann CH; Belli C; Dahl T; Herrstedt J
    Support Care Cancer; 2013 Dec; 21(12):3425-31. PubMed ID: 23949739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Efficacy of Palonosetron Plus Dexamethasone in Preventing Chemoradiotherapy-induced Nausea and Emesis in Patients Receiving Daily Low-dose Cisplatin-based Concurrent Chemoradiotherapy for Uterine Cervical Cancer: A Phase II Study.
    Mitsuhashi A; Usui H; Nishikimi K; Yamamoto N; Hanawa S; Tate S; Watanabe-Nemoto M; Uno T; Shozu M
    Am J Clin Oncol; 2017 Apr; 40(2):118-121. PubMed ID: 25144265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aprepitant versus metoclopramide, both combined with dexamethasone, for the prevention of cisplatin-induced delayed emesis: a randomized, double-blind study.
    Roila F; Ruggeri B; Ballatori E; Fatigoni S; Caserta C; Licitra L; Mirabile A; Ionta MT; Massidda B; Cavanna L; Palladino MA; Tocci A; Fava S; Colantonio I; Angelelli L; Ciuffreda L; Fasola G; Zerilli F
    Ann Oncol; 2015 Jun; 26(6):1248-1253. PubMed ID: 25743855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of fosaprepitant for the prevention of nausea and emesis during 5 weeks of chemoradiotherapy for cervical cancer (the GAND-emesis study): a multinational, randomised, placebo-controlled, double-blind, phase 3 trial.
    Ruhlmann CH; Christensen TB; Dohn LH; Paludan M; Rønnengart E; Halekoh U; Hilpert F; Feyer P; Kristensen G; Hansen O; Keefe D; Herrstedt J
    Lancet Oncol; 2016 Apr; 17(4):509-518. PubMed ID: 26952945
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.